Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
1998-5-13
pubmed:abstractText
The less differentiated stage (CD10-) of B-lineage acute lymphoblastic leukaemia (ALL) described as preB1-ALL in the GEIL nomenclature, accounts for less than 10% of ALL. It is classically considered to be associated with translocation (4;11)(q21;q23), and to have a poor prognosis. We report an extensive immunophenotypic, genomic and clinical study of a series of 64 preB-1 ALL patients, representing 6.3% of a cohort of consecutive ALLs. The engagement of preB1-ALL cells in the B-lineage was confirmed by their B-lineage score, equal to or higher than 2. In addition, more than 90% of the cases tested showed rearranged IGH genes. Translocation (4;11) was the most frequent karyotypic anomaly seen, but only accounted for 24% of the preB1-ALL cases tested. Expression of the myeloid associated antigen CD15 was also found with high incidence in this subset. Clinical and biological features at presentation showed more significant differences between preB1- and T-ALL than between preB1- and preB2-ALL (CD10+). However, outcome characteristics of the 22 children with preB1-ALL confirmed the worse prognosis of this entity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
329-42
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9517504-Adolescent, pubmed-meshheading:9517504-Adult, pubmed-meshheading:9517504-Anthracyclines, pubmed-meshheading:9517504-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9517504-Asparaginase, pubmed-meshheading:9517504-Burkitt Lymphoma, pubmed-meshheading:9517504-Child, pubmed-meshheading:9517504-Child, Preschool, pubmed-meshheading:9517504-Cortisone, pubmed-meshheading:9517504-Cyclophosphamide, pubmed-meshheading:9517504-Daunorubicin, pubmed-meshheading:9517504-Female, pubmed-meshheading:9517504-Gene Rearrangement, T-Lymphocyte, pubmed-meshheading:9517504-Humans, pubmed-meshheading:9517504-Immunoglobulin Heavy Chains, pubmed-meshheading:9517504-Immunophenotyping, pubmed-meshheading:9517504-Infant, pubmed-meshheading:9517504-Leukemia-Lymphoma, Adult T-Cell, pubmed-meshheading:9517504-Male, pubmed-meshheading:9517504-Methotrexate, pubmed-meshheading:9517504-Neprilysin, pubmed-meshheading:9517504-Outcome Assessment (Health Care), pubmed-meshheading:9517504-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:9517504-Prednisone, pubmed-meshheading:9517504-Prognosis, pubmed-meshheading:9517504-Steroids, pubmed-meshheading:9517504-Vincristine
pubmed:year
1998
pubmed:articleTitle
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies.
pubmed:affiliation
Laboratoire Hématologie et Service de Pédiatrie, C.H.U. Charles Nicolle, Rouen, France.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study